melphalan and Diabetes-Mellitus--Type-1

We describe the first reported pediatric patient to our knowledge with a spindle cell pseudotumor caused by Mycobacterium genavense in a hematopoietic stem cell transplant recipient, and review the literature of such an entity in the transplant population.

Topics: Abdomen; Adolescent; Alemtuzumab; Antibiotic Prophylaxis; Antibiotics, Antitubercular; Antibodies, Monoclonal, Humanized; Bone Marrow Transplantation; Bronchoalveolar Lavage Fluid; Cyclosporine; Diabetes Mellitus, Type 1; Diarrhea; Genetic Diseases, X-Linked; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Immune System Diseases; Immunosuppressive Agents; Lymph Nodes; Male; Melphalan; Mycobacterium Infections, Nontuberculous; Mycophenolic Acid; Nontuberculous Mycobacteria; Photopheresis; Polymerase Chain Reaction; Transplantation Conditioning; Vidarabine

Bilateral exudative macular detachments were present on a 64-year-old diabetic Caucasian male who presented with bilateral blurring of vision. Besides the exudative macular detachments there was no diabetic retinopathy or congestive retinopathy, and a previous fluorescein angiogram revealed no focal leakage. Laboratory investigation, bone marrow biopsy, and a bone survey revealed the diagnosis of multiple myeloma.

Topics: Diabetes Mellitus, Type 1; Exudates and Transudates; Humans; Macula Lutea; Male; Melphalan; Middle Aged; Multiple Myeloma; Plasmapheresis; Prednisolone; Retinal Detachment; Visual Acuity

Topics: Blood Glucose; Blood Proteins; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Fructosamine; Glucocorticoids; Glycated Hemoglobin; Hexosamines; Humans; Insulin; Melphalan; Middle Aged; Multiple Myeloma; Paraproteinemias; Recurrence; Serum Albumin

We report the case of a patient with scleromyxedema with abnormal monoclonal gamma globulin of the kappa type who was treated with melphalan (Alkeran), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighting the benefits and risks of melphalan treatment.

Topics: Adult; Diabetes Mellitus, Type 1; Humans; Leukemia, Myeloid; Male; Melphalan; Paraproteinemias; Scleroderma, Systemic